Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

Occupational studies stretching back decades have found an increased risk of bladder cancer among hairdressers.

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

New Zealand women with ovarian cancer finally have funded access to bevacizumab. Pharmac’s announcement yesterday comes ten years after the treatment was funded in Australia, and follows a long fight ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...